Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How To Conduct A Multi-Company Trial For Rare Pediatric Diseases

Executive Summary

US FDA draft guidance suggests efficacy endpoints for testing multiple drug products in the same clinical trials; advances an FDA-EMA joint proposal promoting innovative approaches for development of Gaucher disease medicines.


Related Content

Gene Therapy Guidances Will Focus On Specific Diseases, Gottlieb Says
Regenerative Medicine Clinical Trials: US FDA Supports Studies Comparing Multiple Agents
Master Protocols Are Both Welcome And Inevitable – US FDA's Woodcock
Multi-Company, Multi-Product Clinical Trials On The Cards For Rare Pediatric Diseases





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts